2,247 press releases in English indexed under biotech & pharma.
Fort Wayne Medical Oncology and Hematology and Fort Wayne Gynecologic Oncology Consolidate Bluffton and Decatur Clinics at New Decatur Location
AbbVie (NYSE: ABBV), a global pharmaceutical leader, and the PGA TOUR today announced a partnership naming AbbVie the Official Pharmaceutical Sponsor ...
CHICAGO, Sept. 15, 2026 -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, today announced that Board member Ramiro Guerrero, JD, LL.M. has increased his ownership stake in the Company through open market purchases totaling approximately $252,284. A total of 185,078 shares of MAIA common stock were acquired by Mr. Guerrero between August 20, 2026, and September 10, 2026, at an average common stock price of $1.36. MAIA also announced that 73,000 shares of MAIA common stock were acquired by Founder and CEO Vlad Vitoc, M.D. on September 14, 2026, at an average common stock price of $1.37.
SAN FRANCISCO, Sept. 15, 2026 -- Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit. Investors who purchased or acquired Aardvark common stock...
SANTA ANA, Calif., Sept. 15, 2026 -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that NKGen Chairman and Chief Executive Officer Paul Y. Song, M.D., will present on the Company’s lead investigational program, troculeucel, at the 4th Great Bay Cell and Gene Therapy Forum, taking place September 22-23, 2026, in Guangzhou, China.
NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM
Shanghai, China--(September 14, 2026) - Frost & Sullivan has conducted comprehensive research on the global gut microbiota industry and published the "White Book on the Current Landscape and Future Trends of the Gut Microbiota Industry". The white paper provides a comprehensive overview of gut microbiota, exploring its relationship with health and disease, the current landscape of gut microbiota drug development, market insights, and future trends. The White Book begins by...
COPENHAGEN, Denmark, Sept. 14, 2026 -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its Board of Directors has authorized the Company to repurchase up to $400 million of the Company’s ordinary shares (the Share Repurchase Program).
Dayton, Ohio--(September 14, 2026) - Alyea Therapeutics, a wholly owned subsidiary of AIFC Corporation (NASDAQ: AIFC), is pleased to announce its participation in the upcoming 3rd Annual ArcStone-Kingswood Growth Summit in Toronto, taking place on September 16, 2026, at the Sheraton Centre Toronto Hotel. Amol Soin, MD, Chief Executive Officer of Alyea Therapeutics, will participate as a Featured Company and will hold one-on-one meetings with interested investors and capital...
The post Inside the pharmaceutical industry’s AI shift appeared first on Source.
The post How pharmaceutical leaders are operationalizing AI appeared first on Source.
Company announcement No. 48 / 2026